| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2013: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Development of new targeted therapy for primary refractory or relapse leukemia in childhood is needed to overcome cellular resistance to current chemotherapy. We previously reported genetic modification of primary human NK cells by enforced expression of anti-CD19 chimeric receptors linked to CD3 zeta; (1st generation chimeric receptor) and CD3 zeta plus 4-1BB signaling molecules (2nd generation) could markedly enhanced cytotoxicity against leukemic cells. To further enhance cellular functions, we developed the 3rd generation chimeric receptor with triple signaling molecules. The novel construct of the 3rd generation was successfully transduced with primary NK cells. Surface expression of the chimeric receptors was relatively low compared to 1st and 2nd generation, however, the function of cytotoxicity was confirmed as same level as previous generations. We plan to assess the potential for further improvement of surface expression and function of the 3rd chimeric receptor.
|
